A new study has found notable improvements in mental health among participants who underwent legal, supervised sessions with psychedelics in Oregon, the first state to legalize such services for adults. Published by Osmind, a mental health research and electronic health record company, the study analyzed treatment outcomes from individuals seeking relief from depression and anxiety under Measure 109 in Oregon. This 2020 voter-approved initiative decriminalized psilocybin, the psychoactive compound in psychedelic mushrooms, for therapeutic use by adults over 21 in state-licensed centers. While clinical trials have hinted at psilocybin’s potential at scale, this report offers early evidence from a commercial setting.
The Osmind study relies on voluntary self-reports, making it “naturalistic” research that captures how these services perform outside the strict protocols of randomized trials (measuring outcomes through self-reported surveys is standard practice in real-world scientific research). The study tracked 88 participants and used standardized tools to measure changes: the PHQ-8 questionnaire for depression (a scale from 0 to 24, where higher scores indicate worse symptoms), the GAD-7 for anxiety, and the WHO-5 for overall well-being. Assessments occurred before the session, one day after, and a month later. No dosages were specified, but sessions followed state guidelines for supervised administration.
Results showed meaningful gains across the board. Depression scores on the PHQ-8 fell by an average of 4.6 points, shifting participants from moderate to mild severity, a change that meets the threshold for clinical significance. Anxiety dropped by 4.8 points (on the GAD-7 scale), and well-being rose by 10.7 points (on the WHO-5 index). No serious adverse events occurred during sessions, though 3 percent reported lingering issues, like heightened anxiety or family strain, a month later. These preliminary improvements suggest that psilocybin could offer rapid relief in a legal therapeutic setting, aligning with the compound’s reputation for fostering emotional resilience.
Direct comparisons to other psilocybin studies or clinical trials are tricky, as many rely on different scales, populations, and measures. Some studies report quantified outcomes (“effect size”) in the proportion of participants who had meaningful changes, while others report changes in a particular scale. As an example, in one randomized study, about two-thirds of participants continued to experience relief from major depressive disorder (MDD) remission five years after receiving treatment. That study only included participants diagnosed with major depression and measured outcomes with a different metric (the GRID-HAMD scale) than the Oregon study.
Nonetheless, Osmind’s review of real-world data reveals significant results on depression and anxiety, consistent with more medicalized clinical trials. Oregon’s approach to psychedelic treatment is a novel experiment, not just because it uses psychedelics, but because it created an entirely new mental health services framework. The state had to design training criteria for schools so that non-medical professionals could learn to administer a drug that is currently undergoing drug trials. By law, these “facilitators” did not need prior mental or medical training.
This new study shows promise for both the impact of psychedelics as a mental health treatment and for lowering the cost of licensed mental health services. Psychedelic therapy can be very expensive (over $15,000) when using a medical model, where two licensed therapists see a single patient for three extended sessions (based on countries where it is federally legal). In Oregon, professionals do not need to attend medical school and can administer group sessions, reducing the total cost per patient.
The Drug Enforcement Administration (DEA) has requested that Health and Human Services (HHS) review whether psilocybin should continue to be banned as a Schedule I drug (the DEA request was publicly confirmed by Kathryn Tucker, JD, who is involved with the case; it was also confirmed privately by legal counsel to Reason staff). A Schedule I designation reflects the government’s opinion that the substance has no medical value and is highly susceptible to abuse. Businesses that traffic in Schedule I substances, including Oregon psilocybin clinics, are considered federal criminal enterprises, are generally unable to access financial services, and are prohibited from claiming deductions on their federal income taxes using the “ordinary and necessary” standard that applies to other businesses. These federal penalties significantly increase the cost and risk faced by these businesses, and these additional financial burdens must be passed on to customers.
Data collected by Reason Foundation shows that states with legal psychedelic services do not display increased rates of criminal activity or hospitalizations. Taken together with this latest study, data from Oregon makes a strong case that psilocybin holds clear medical value and does not endanger public health, calling into question whether it should be considered a Schedule I drug.